XCancer

The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer

Description:

This study is a prospective, single-arm, open-label, dose-escalation study. A total of 5 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles. After each dose group completed the enrollment and DLT observation, based on the participant's safety tolerance, radiation dosimetry, and preliminary efficacy evaluation results, it was decided whether to adjust the dose of the subsequent dose groups or to suspend the dose escalation.

Sponsor:

FindCure Biosciences (ZhongShan) Co., Ltd.

Phase:

Early Phase 1

Contacts:

Chunjing Yu (PRINCIPAL_INVESTIGATOR)

Tingjin Wang (CONTACT)

wangtingjin@find-cure.com

18664044814

Government Study Link:

NCT07542379 - Click here to see study on

ClinicalTrials.gov

FC516

Isotope(s):
Target(s):
  • ACP3
Ligand Class: Small Molecules
Inclusion
  • Patients with metastatic castration-resistant prostate cancer who have failed standard treatments.
  • According to RECIST 1.1, there is at least one measurable lesion.
Exclusion
  • Central nervous system metastases with clinical symptoms.